- Home
- GNPX vs BFRI Comparison
GNPX vs BFRI Comparison
Compare GNPX & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- BFRI
- Stock Information
- Founded
- GNPX 2009
- BFRI 1997
- Country
- GNPX United States
- BFRI United States
- Employees
- GNPX N/A
- BFRI N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- BFRI Biotechnology: Pharmaceutical Preparations
- Sector
- GNPX Health Care
- BFRI Health Care
- Exchange
- GNPX Nasdaq
- BFRI Nasdaq
- Market Cap
- GNPX 10.8M
- BFRI 10.6M
- IPO Year
- GNPX 2018
- BFRI 2021
- Fundamental
- Price
- GNPX $6.64
- BFRI $1.06
- Analyst Decision
- GNPX
- BFRI Strong Buy
- Analyst Count
- GNPX 0
- BFRI 1
- Target Price
- GNPX N/A
- BFRI $2.75
- AVG Volume (30 Days)
- GNPX 1.7M
- BFRI 93.2K
- Earning Date
- GNPX 11-14-2025
- BFRI 11-13-2025
- Dividend Yield
- GNPX N/A
- BFRI N/A
- EPS Growth
- GNPX N/A
- BFRI N/A
- EPS
- GNPX N/A
- BFRI N/A
- Revenue
- GNPX N/A
- BFRI $39,188,000.00
- Revenue This Year
- GNPX N/A
- BFRI $9.70
- Revenue Next Year
- GNPX N/A
- BFRI $12.58
- P/E Ratio
- GNPX N/A
- BFRI N/A
- Revenue Growth
- GNPX N/A
- BFRI 11.20
- 52 Week Low
- GNPX $6.51
- BFRI $0.54
- 52 Week High
- GNPX $140.00
- BFRI $2.22
- Technical
- Relative Strength Index (RSI)
- GNPX 63.07
- BFRI 56.80
- Support Level
- GNPX $7.71
- BFRI $0.95
- Resistance Level
- GNPX $9.89
- BFRI $1.15
- Average True Range (ATR)
- GNPX 1.15
- BFRI 0.06
- MACD
- GNPX 0.53
- BFRI 0.00
- Stochastic Oscillator
- GNPX 50.54
- BFRI 64.00
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.